Partial
Partially Aligned
Patient Risk:
Low
Summary
One claim matches the label’s metastatic NSCLC PD-L1 (TPS ≥1%) indication as determined by an FDA-authorized test, but the included timing/approval-year detail (2014) is not supported by the provided label text. The second claim about initial FDA approval in 2014 for a PD-1 inhibitor is not supported by the provided label sections.
Category Scores
Accurate Statements
Keytruda is indicated for metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-authorized test.
Label section 1.2: “KEYTRUDA, as a single agent, is indicated for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-authorized test [see Dosage and Administration (2.1)] …”
Unsupported Statements
In 2014, Keytruda gained FDA approval for the treatment of patients with metastatic NSCLC whose tumors expressed PD-L1, as determined by an FDA-approved test.
The provided label excerpt supports the PD-L1 (TPS ≥1%) metastatic NSCLC indication, but does not include any year or approval timing (2014).
The initial FDA approval of Keytruda in 2014 was for a PD-1 inhibitor.
The provided label sections do not state initial approval year (2014) or that the initial approval was for a PD-1 inhibitor.
Contradictions
Important Omissions
Approval timing/year (2014) and initial approval characterization (PD-1 inhibitor) details are not present in the supplied label text.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Discrepancies are related to approval-history/timing and mechanism characterization, not dosing, contraindications, boxed warnings, or safety monitoring within the provided claims.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Partially Aligned
Primary Issue
Approval year (2014) and initial approval/PD-1 inhibitor characterization are not supported by the provided label sections.
Suggested Improvement
Remove or rephrase approval-year/timing and initial-approval mechanism claims; limit indication statements to the label-supported metastatic NSCLC PD-L1 (TPS ≥1%) with an FDA-authorized test.